Instituto Catalán de Oncologia
Number of employees: 988
The research group is formed by a multidisciplinary team of biologists, statisticians, computer scientists and clinical specialists. The group belongs to the Catalan Institute of Oncology (ICO), a public comprehensive cancer center in the campus of Bellvitge (L’Hostitalet, Barcelona), partner of the School of Medicine of the University of Barcelona. The group, consolidated in 1995, has been investigating the genetic alterations in colorectal cancer in different aspects. An epidemiologic case-control study about genetic and environmental risk factors for colorectal cancer was performed during 1996-98. We have evaluated the association between the exposition to carcinogenic agents and a spectrum of mutations in the genes K-ras and p53, microsatellite instability and genetic polymorphisms in genes related to metabolism, inflammation, DNA repair and response to treatment. The biological samples of this study form a tumor bank that will be the source of samples for this project. A reduced set of these samples has also been studied with expression microarrays and CGH. Our group has also being doing novel research in epigenetics, defining the role of global methylation patterns in colorectal cancer. Also, plasmas of these patients (cases and controls) are being currently analyzed with MALDI-TOF techniques with the aim of finding proteomic profiles relevant for diagnosis and prognosis. In parallel to these clinical and biological researches, we have consolidated a Biomarkers and Susceptibility Unit with interest in apply methods and tools for analysis of genetic profiles and the study of gene-networks for prognosis and diagnostic biomarkers discovery.
Dr. Víctor Moreno is associate professor of preventive medicine of the University of Barcelona, director of the Programme of Cancer Prevention and Unit of Biomarkers and Susceptibility leader, at ICO. He is an epidemiologist with special interest in methodological aspects and biostatistics. He designed and conducted the case-control study that provides the samples for the proposal and has coordinated the research activities of ICO in colorectal cancer. He is co-investigator in MECC study, a large case-control study on colorectal cancer carried out in Israel in a collaboration with the University of Michigan and the Technion Israel Institute of Technology in Haifa.
Dr. Gabriel Capellà, director of the Translational Laboratory of ICO and Research Director of IDIBELL Foundation, has long experience in clinical and molecular research of colorectal cancer. He has been Principal Investigator of the projects on expression profiling of tumors using microarray techniques. His research group is interested in hereditary colorectal cancer, the use of genetic alterations in non-invasive diagnosis of colorectal tumors and in the search of novel prognostic markers both in local and disseminated disease.
Dr. Ramón Salazar, ICO oncologist responsible for recruitment, quality of the clinical information and follow-up of the patients.
Elisabet Guinó, ICO senior researcher of the Biomarkers and Susceptibility Unit with expertise in systems biology projects aiming to identify new cancer genes by reverse-engineering and gene regulatory networks.
Xavier Solé, ICO senior researcher of the Biomarkers and Susceptibility Unit with expertise in bioinformatics, systems biology, integrative data analysis, gene regulatory networks, geneome-wide association studies, microarray analysis and molecular basis of cancer genetics.
David Cordero, ICO researcher of the Biomarkers and Susceptibility Unit with expertise in bioinformatics, computational systems biology of cancer, machine learning, predictive models, high-throughput data analysis, biomarkers discovery and proteomics.
Solé X, Bonifaci N, López-Bigas N, Berenguer A, Hernández P, Reina O, Maxwell CA, Aguilar H, Urruticoechea A, de Sanjosé S, Comellas F, Capellá G, Moreno V, Pujana MA. Biological convergence of cancer signatures. PLoS ONE. 2009;4(2):e4544.
Solé X, Gonzalez JR, Moreno V. Analysis of Population-Based Genetic Association Studies Applied to Cancer Susceptibility and Prognosis. Computational Biology: Issues and Applications in Oncology, Applied Bioinformatics and Biostatistics in Cancer Research Chapter 7. T Pharm (ed.) 2009.
Mayor R, Casadomé L, Azuara D, Moreno V, Clark SJ, Capellà G, Peinado MA. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br J Cancer 2009; 100(10):1534-9.
Taioli E, Garza MA, Ahn YO, Bishop DT, Bost J, Budai B, Chen K, Gemignani F, Keku T, Lima CS, Le Marchand L, Matsuo K, Moreno V, Plaschke J, Pufulete M, Thomas SB, Toffoli G, Wolf CR, Moore CG, Little J. Meta- and Pooled Analyses of the Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Colorectal Cancer: A HuGE-GSEC. Am J Epidemiol.2009.
Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho LP, Ben-Izhak O, Cohen HI, Trougouboff P, Bejhar J, Sova Y, Pinchev M, Rennert G, Gruber SB. Pathologic Predictors of Microsatellite Instability in Colorectal Cancer. Am J Surg Pathol 2009;33(1): 126-33.
de Oca J, Azuara D, Sanchez-Santos R, Navarro M, Capella G, Moreno V, Sola A, Hotter G, Biondo S, Osorio A, Marti-Rague J, Rafecas A. Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer. Int J Colorectal Dis. 2008;23(1):21-27.
Gonzalez JR, Armengol L, Solé X, Guino E, Mercader JM, Estivill X, Moreno V. SNPassoc: an R package to perform whole genome association studies. Bioinformatics. 2007 Jan 31.
Hernandez P, Solé X, Valls J, Moreno V, Capella G, Urruticoechea A, Pujana MA. Integrative analysis of a cancer somatic mutome. Mol Cancer. 2007 Feb 5;6:13.
Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, Gonzaalez S, Guino E, Capella G, Canzian F. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 2006; 12: 2101-8.
Frigola J, Solé X, Paz MF, Moreno V, Esteller M, Capella G, Peinado MA. Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum Mol Genet. 2005; 14: 319-26.
Kopelovich L, Lipkin S, Rennert G, Gruber S, Moreno V. “Identification of subjects likely to benefit from statin therapy”. (2008) PCT/US2008/082359 – E-328-2007/0-PCT-02.
Peinado MA, Risques RA, Vendrell E, Capellà G, Grau M, Obrador A, Tarafa G, Moreno V, Solé X, Rosell E, Piulats J. “Genetic analysis of biological samples in arrayed expanded representations of their nucleic acids”. WO 02/09937.
Fernández V, Campo E, Hartmann E, Moreno V, Rosenwald A. “Method and kit for predicting survival of patients with mantle cell lymphoma”. ES 200703071.
Staudt L, Wright G, Dave S, Tan B, Powell J, Wilson W, Jaffe E, Chan W, Greiner T, Weisenburger D, Armitage J, Fu K, Fisher R, Rimsza L, Miller T, Grogan T, Campo E, Bea S, Salaverria I, Lopez-Guillermo A, Montserrat E, Moreno V, Zettl A, Ott G, Muller-Hermelink H, Rosenwald A, Vose J, Gascoyne R, Connors J, Smeland E, Kvaløy S, Holte H, Delabie J, Andrew T. “Methods for identifying, diagnosing, and predicting survival of lymphomas”. US Application Nº 11/493,387.